CBIO Q3 2022 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$256,031

Operating Income

-$9M

Net Income

-$9M

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$913,979

Balance Sheet

Total Assets

$56M

Total Liabilities

$8M

Stockholders' Equity

$48M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$86,560	-100.0%
Gross Profit	-$256,031	$86,560	-395.8%
Operating Income	-$9M	-$17M	+49.4%
Net Income	-$9M	-$17M	+50.8%